

Eluminex Further Expands Leadership Team and Receives New Awards

- *Dr. Chunlin Yang joined Eluminex as Vice President of Technology Development*
- *Dr. Jinzhong Zhang was Selected as Suzhou Industrial Park Leading Talent in Science and Technology and Suzhou City Leading Talent in Science and Technology*

SUZHOU, China, January 5, 2022 — Eluminex Biosciences (Suzhou) Limited (Eluminex), a venture-backed, clinical stage ophthalmology-focused biotechnology company headquartered in Suzhou, China with a U.S. subsidiary located in San Francisco Bay Area, California, announced another key senior appointment as part of the current corporate scale-up plan to support their newly opened research and development center in Suzhou BioBay.

Chunlin Yang, PhD, joined Eluminex as the Vice President of Technology Development, responsible for the research and development and commercialization of the company's recently licensed recombinant human collagen and biosynthetic cornea technologies from the United States. With over 20 years of experience in biomaterials, biopolymers, and tissue engineering, Dr. Yang has held senior roles at FibroGen where he led the development of a biosynthetic cornea using recombinant human collagen. At Johnson & Johnson, he developed a novel biosynthetic composite technology for reconstructive surgery and soft tissue replacement and served as a Research Fellow in the Advanced Technologies and Regenerative Medicine (ATRM) unit and the Center for Biomaterials and Advanced Technologies (CBAT). His scientific accomplishments have been recognized within the industry and awarded the J&J Excellence in Science Award and has authored over 40 patent applications and more than 30 scientific papers in the fields of collagen-based biomaterials, medical devices, controlled drug delivery, and

tissue engineering. Dr. Yang received his PhD in Biochemistry through the joint program of the Chinese Academy of Sciences in Beijing and Medical University of Luebeck, Germany and completed his post-doctoral fellowships at Medical University of Luebeck, the National Institutes of Health, and Thomas Jefferson University.

Jinzhong Zhang, PhD, was Selected as Suzhou Industrial Park Leading Talent in Science and Technology and Suzhou City Leading Talent in Science and Technology. Dr. Zhang is Co-founder, Chairman and CEO of Eluminex. Under his leadership, Eluminex has built one of the most globally leading teams and portfolios in the focused ophthalmology therapeutic area within a very short time. He has a long and accomplished career in the ophthalmology field and was in senior executive positions with multiple companies. He started and established his career in academic across different countries prior to joining the industry 15 years ago.

About Eluminex Biosciences

Eluminex Biosciences is a privately-held clinical-stage biopharmaceutical biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. Eluminex is devoted towards innovating the next generation of first-in-class or best-in-class ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. In addition to the bioengineered cornea (EB-301), Eluminex has developed a pipeline of next generation multivalent protein therapeutics for retinal diseases (EB-101, EB-102, EB-105, and EB-107) including age-related macular degeneration, macular edema, and diabetic retinopathy; these assets are wholly owned and developed by Eluminex. The Eluminex global headquarters and research and development center are located in Suzhou BioBay Industrial Park, China with a US-subsubsidiary located in the San Francisco Bay Area. Eluminex is supported by three premiere global life

science venture funds: Lilly Asia Ventures, Hill House Capital, and Quan Capital. For more information, please visit www.eluminexbio.com.

典晶生物首席执行官张金忠博士荣膺两项人才称号并宣布进一步扩大公司高级管理层

- 张金忠博士荣膺“苏州工业园区科技领军人才”和“姑苏创新创业领军人才”两项称号
- 杨春林博士加入典晶生物，担任技术开发副总裁

今年 8 月及 12 月，典晶生物共同创始人，董事长及首席执行官张金忠博士荣膺苏州工业园区科技领军人才以及姑苏创新创业领军人才两项称号。苏州工业园区科技领军人才是苏州工业园区为加快推进世界一流高科技园区建设，进一步加大高层次创新、创业领军人才（团队）引进力度，不断提升园区创新源地、产业高地建设水平而设立的高层次人才项目。姑苏创新创业领军人才计划是苏州市深入实施创新驱动发展战略，着力打造科技强市和建设“创业者乐园，创新者天堂”，为苏州打造向世界展示社会主义现代化的“最美窗口”而设立的科技人才保障工程。

典晶生物 2020 年 9 月在苏州工业园区落户，在短短一年多的时间里公司在张金忠博士的带领下，迅速建立起了一支在眼科领域世界一流的管理团队，并搭建了一条具有差异化优势的产品管线。张金忠博士在眼科研究和药物开发方面拥有 25 年的丰富经验，曾在多家私营和大型全球眼科公司担任高级领导职务，参与了多个上市产品的研发和商业化。

杨春林博士应邀加入典晶生物，担任技术开发副总裁，负责公司最近从美国引进的重组人胶原蛋白和生物合成角膜的研发和产业化。杨博士在生物材料、天然生物高分子材料及组织工程领域拥有 20 多年产品研发的经验。他曾在珐博进公司担任高级职务，负责利用重组人胶原蛋白开发生物合成角膜。在这之前，他曾在强生公司的先进技术和再生医学部门 (ARTM) 以及生物材料和先进技术中心 (CBAT) 担任研究员 (Research Fellow)。杨春林博士的科学成就在业界得到广泛认可，曾荣获强生公司卓越科学奖 (J&J Excellence in Science Award)，在胶原生物材料、医疗器械、药物缓释和组织工程领域申请了 40 多项专利并撰写了 30 多篇科学论文。杨春林通过中国科学院

与德国 Luebeck 医科大学联合教育项目获得生物化学博士学位，并在 Luebeck 医科大学、美国国立卫生研究院 (NIH) 和 Thomas Jefferson 大学完成博士后研究。

关于典晶生物

典晶生物是一家处于临床阶段的生物技术公司，专注于创新疗法在全球的开发和商业化，以满足眼科疾病治疗和管理方面未满足的需求。典晶生物致力于开发同类首个或者同类最优的眼科治疗方法，减少眼科疾病对患者视力的威胁和由此带来的生活不便。除了生物合成角膜项目 (EB-301)，典晶生物目前正在研发一系列用于治疗视网膜疾病 (EB-101、EB-102、EB-105 和 EB-107) 的下一代生物疗法。这些管线产品均为典晶生物全权拥有和独家开发。典晶生物全球总部和研发中心位于中国苏州生物医药产业园区，美国子公司位于加州旧金山湾区。典晶生物获得了三家顶级风险投资基金的支持：礼来亚洲基金、高瓴创投和泉创资本。如需了解更多信息，请访问 www.eluminexbio.com。